PURPOSE: To report the change over time in intraocular pressure in patients treated with topical timolol or placebo.METHODS: Ninety patients with untreated ocular hypertension, defined as elevated intraocular pressure and normal visual fields, were randomly assigned to treatment and prospectively observed at 3-month intervals for up to 10 years in a double-masked fashion. The study end point was one eye showing reproducible glaucomatous field defects; patients were also withdrawn if one eye showed intraocular pressure of 35 mm Hg or higher. For each treatment group and visit, the mean and median of all intraocular pressure measurements were calculated. Medians were also calculated for the timolol group, assuming a worst-case scenario in whi...
Objectives: To characterize intraocular pressure (IOP) changes during 6 years of follow-up among pat...
OBJECTIVE: To estimate the intraocular pressure (IOP)-lowering effect of prostaglandin analogs (PGAs...
Sakurako Takeda,1,2 Tatsuya Mimura,1 Masao Matsubara1,2 1Department of Ophthalmology, Tokyo Women&r...
BACKGROUND: Increased intraocular pressure (IOP) has been shown to be one of the most important risk...
Purpose: To assess the impact of 2 strategies for initiating therapy in ocular hypertension (OH) on ...
AIM: To draw a Meta-analysis over the comparison of the intraocular pressure (IOP)-lowering efficacy...
PURPOSE: To compare the around-the-clock intraocular pressure (IOP) reduction induced by timolol 0.5...
BACKGROUND: Given the growing number of ocular hypotensive medications available, it is important to...
BACKGROUND: The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), a...
Background: Prospective, observational studies that enroll large numbers of patients with few exclus...
AIM: To evaluate intraocular pressure (IOP)-lowering effect and ocular tolerability of brimonidine/t...
PURPOSE: To compare intraocular pressure (IOP) after adding either latanoprost or pilocarpine to...
To investigate pattern electroretinogram changes in treated ocular hypertension, we evaluated patter...
The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), and the fixed...
Background: The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), a...
Objectives: To characterize intraocular pressure (IOP) changes during 6 years of follow-up among pat...
OBJECTIVE: To estimate the intraocular pressure (IOP)-lowering effect of prostaglandin analogs (PGAs...
Sakurako Takeda,1,2 Tatsuya Mimura,1 Masao Matsubara1,2 1Department of Ophthalmology, Tokyo Women&r...
BACKGROUND: Increased intraocular pressure (IOP) has been shown to be one of the most important risk...
Purpose: To assess the impact of 2 strategies for initiating therapy in ocular hypertension (OH) on ...
AIM: To draw a Meta-analysis over the comparison of the intraocular pressure (IOP)-lowering efficacy...
PURPOSE: To compare the around-the-clock intraocular pressure (IOP) reduction induced by timolol 0.5...
BACKGROUND: Given the growing number of ocular hypotensive medications available, it is important to...
BACKGROUND: The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), a...
Background: Prospective, observational studies that enroll large numbers of patients with few exclus...
AIM: To evaluate intraocular pressure (IOP)-lowering effect and ocular tolerability of brimonidine/t...
PURPOSE: To compare intraocular pressure (IOP) after adding either latanoprost or pilocarpine to...
To investigate pattern electroretinogram changes in treated ocular hypertension, we evaluated patter...
The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), and the fixed...
Background: The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), a...
Objectives: To characterize intraocular pressure (IOP) changes during 6 years of follow-up among pat...
OBJECTIVE: To estimate the intraocular pressure (IOP)-lowering effect of prostaglandin analogs (PGAs...
Sakurako Takeda,1,2 Tatsuya Mimura,1 Masao Matsubara1,2 1Department of Ophthalmology, Tokyo Women&r...